Antidiabetic effect and mechanism of chitooligosaccharides.
The aim of this study was to observe the antidiabetic effect and mechanism of chitooligosaccharides (COS). Type 2 diabetic rats were fed a high-energy diet together with an injection of streptozotocin (STZ). After 8 weeks of COS treatment, the changes in glycometabolism, insulin sensitivity, serum hepatic marker enzyme levels, liver glycogen content, expressions of glucose transporter GLUT-4, malonaldehyde content, superoxide dismutase activity and morphology of the pancreas were observed. The results showed that COS significantly reduced fasting blood glucose (FBG), fasting insulin (FINS), increased the insulin sensitivity index (ISI) and improved oral glucose tolerance. COS increased liver glucokinase activity and glycogen content and upregulated the expressions of GLUT-4 mRNA in adipose and soleus muscle. They also raised the superoxide dismutase activity and reduced the malonaldehyde content in pancreas homogenate. Pancreas hematoxylin/eosin (HE) staining of the diabetic rats showed ruptured islet, but changes of pancreatic islet in the animals were minimized by administration of COS. The effect of COS on pancreatic beta cell (INS-1) in vitro was also examined. It was found that COS played important roles in INS-1 cells by promoting proliferation, increasing glucose stimulated insulin release, upregulating the expressions of GLUT-2 mRNA and protecting against STZ-induced apoptosis. The results from the present study indicate COS have protective effect for type 2 diabetes by ameliorating insulin resistance, promoting the proliferation of beta cells, increasing insulin secretion and protecting beta cells.
Ju
Chuanxia
C
Pharmaceutical Department, Medical College of Qingdao University, and Cardiovascular Department, The Affiliated Hospital of Medical College of Qingdao University, Qingdao, Shandong, China.
Yue
Wang
W
Yang
Zhihong
Z
Zhang
Quanfang
Q
Yang
Xue
X
Liu
Zhantao
Z
Zhang
Fang
F
D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D048271:Chitosan / Q000494:pharmacology / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050417:Insulin-Secreting Cells / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009844:Oligosaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D007004:Hypoglycemic Agents; D009844:Oligosaccharides; D048271:Chitosan